{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '153', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '[Ferrara, N., et al 2003]', 'Ferrara N, Gerber HP, LeCouter J.', '[04XKQ2]', 'The biology of VEGF and its', 'receptors. Nat Med. 2003', 'Jun;9(6):669-76.', '[Havel, L., et al 2014]', 'Havel L, Lee JS, Lee KH, Bidoli P,', '[04X49Z]', 'Kim JH, Ferry D, et al. E7080', '(lenvatinib) in addition to best', 'supportive care (BSC) versus BSC', 'alone in third-line or greater', 'nonsquamous, non-small cell lung', 'cancer (NSCLC) [abstract]. Presented', 'at: The American Society of Clinical', 'Oncology (ASCO) Annual Meeting;', '2014 May 31; Alexandria, VA. J Clin', 'Oncol. 2014 May 20;32(15 suppl).', 'Abstract no. 8043.', '[Hodi, F.S., et al 2014]', 'Hodi FS, Ribas A, Daud A, Hamid O,', '[0465RW]', 'Robert C, Kefford R, et al. Patterns of', 'response in patients with advanced', 'melanoma treated with', 'Pembrolizumab (MK-3475) and', 'evaluation of immune-related response', 'criteria (irRC). J Immunother Cancer.', '2014;2( (Suppl 3): P103.', '[Hunder, N. N., et al 2008]', 'Hunder NN, Wallen H, Cao J,', '[00VMPX]', 'Hendricks DW, Reilly JZ, Rodmyre', 'R, et al. Treatment of metastatic', 'melanoma with autologous CD4+ T', 'cells against NY-ESO-1. N Engl J', 'Med 2008;358(25):2698-703.', '[IB Edition 15-Eisai 2018]', 'Lenvatinib (LENVIMAR,', '[04Z6DS]', \"KISPLYX\u00ae) Investigator's Brochure,\", 'Edition Number 15', '[IB Edition 16 2018 ]', 'KEYTRUDA (pembrolizumab)', '[04W7QW]', 'Investigator Brochure, Edition', 'Number 16, 29-JUN-2018.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '154', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '[Kato, Y., et al 2019]', 'Kato Y, Tabata K, Kimura T, Yachie-', '[057JXY]', 'Kinoshita A, Ozawa Y, Yamada K, et', 'al. Lenvatinib plus anti-PD-1 antibody', 'combination treatment activates', 'CD8(+) T cells through reduction of', 'tumor-associated macrophage and', 'activation of the interferon pathway.', 'PLoS One. 2019 Feb', '27;14(2):e0212513.', '[Kimura, T., et al 2018]', 'Kimura T, Kato Y, Ozawa Y, Kodama [057LPH]', 'K, Ito J, Ichikawa K, et al.', 'Immunomodulatory activity of', 'lenvatinib contributes to antitumor', 'activity in the Hepal -6 hepatocellular', 'carcinoma model. Cancer Sci.', '2018;109:3993-4002.', '[Liang, Kung-Yee and Zeger,', 'Liang K-Y, Zeger SL. Longitudinal', '[00QJ0M]', 'Scott L. 2000]', 'data analysis of continuous and', 'discrete responses for pre-post', 'designs. Sankhya: The Indian Journal', 'of Statistics 2000;62(Series B, Pt.', '1):134-48.', '[Lieu, C., et al 2011]', 'Lieu C, Heymach J, Overman M, Tran [04XKQM]', 'H, Kopetz S. Beyond VEGF:', 'inhibition of the fibroblast growth', 'factor pathway and antiangiogenesis.', 'Clin Cancer Res. 2011 Oct', '1;17(19):6130-9.', '[Limaverde-Sousa, G., et al', 'Limaverde-Sousa G, Sternberg C,', '[04XKQW]', '2014]', 'Ferreira CG. Antiangiogenesis beyond', 'VEGF inhibition: a journey from', 'antiangiogenic single-target to broad-', 'spectrum agents. Cancer Treat Rev.', '2014;40:548-57.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}